{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:08:42Z","timestamp":1788930522343,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To validate the prognostic value of histological treatment response, assessed using the Japan Pancreas Society (JPS) grading system, in patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with neoadjuvant chemotherapy (NAC) followed by surgical resection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed, retrospectively, data from 117 consecutive patients who underwent NAC and curative-intent PDAC resection at Tohoku University Hospital between January 2010 and December 2022. Histological responses were graded using the JPS system. Survival analyses were conducted using Kaplan\u2013Meier estimation and Cox proportional hazards modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Histological Grade 1a, 1b, 2, 3, and 4 responses were observed in 47 (40.2%), 42 (35.9%), 21 (17.9%), 6 (5.1%), and 1 (0.9%) patients, respectively. Patients with a Grade\u2009\u2265\u20092 response had significantly longer overall survival (OS) and significantly higher R0 resection rates than those with Grade 1a or 1b responses (median OS: 118.7 vs. 46.6 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037; 100% vs. 82.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). In a multivariable Cox regression model including RECIST progression status and baseline covariates, JPS Grade\u2009\u2265\u20092 remained significantly associated with better OS (adjusted HR 0.48; 95% CI 0.24\u20130.96;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Substantial histological response (JPS Grade\u2009\u2265\u20092) after NAC is strongly associated with improved OS and higher R0 resection rates in patients with resectable PDAC. The JPS grading system provides a basis for clinically meaningful prognostic stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00595-026-03325-w","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:43:37Z","timestamp":1782197017000},"page":"2406-2419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Japan Pancreas Society grading system"],"prefix":"10.1007","volume":"56","author":[{"given":"Daisuke","family":"Douchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Umino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koetsu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Mizuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Unno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"3325_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"3325_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605\u201317.","journal-title":"N Engl J Med"},{"key":"3325_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet"},{"key":"3325_CR4","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"3325_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/jjco\/hyaa018","volume":"50","author":"F Motoi","year":"2020","unstructured":"Motoi F, Unno M. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Jpn J Clin Oncol. 2020;50:483\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"3325_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00595-019-01786-w","volume":"49","author":"M Unno","year":"2019","unstructured":"Unno M, Hata T, Motoi F. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. Surg Today. 2019;49:295\u20139.","journal-title":"Surg Today"},{"key":"3325_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:439\u201357.","journal-title":"J Natl Compr Canc Netw"},{"key":"3325_CR8","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.ccell.2025.09.009","volume":"43","author":"X Bai","year":"2025","unstructured":"Bai X, Li X, Chen Y, Qiao G, Zhang Q, Ma T, et al. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. Cancer Cell. 2025;43:2259\u201367. e2.","journal-title":"Cancer Cell"},{"issue":"1","key":"3325_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/SLA.0000000000006730","volume":"283","author":"M Unno","year":"2026","unstructured":"Unno M, Motoi F, Matsuyama Y, Satoi S, Toyama H, Matsumoto I, et al. Neoadjuvant Chemotherapy with Gemcitabine and S-1 versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II\/III Prep-02\/JSAP05 Trial. Ann Surg. 2026;283(1):57\u201364.","journal-title":"Ann Surg"},{"key":"3325_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00535-018-1506-7","volume":"54","author":"F Motoi","year":"2019","unstructured":"Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, et al. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol. 2019;54:194\u2013203.","journal-title":"J Gastroenterol"},{"key":"3325_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/PAS.0000000000001853","volume":"46","author":"H Wang","year":"2022","unstructured":"Wang H, Chetty R, Hosseini M, Allende DS, Esposito I, Matsuda Y, et al. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society. Am J Surg Pathol. 2022;46:754\u201364.","journal-title":"Am J Surg Pathol"},{"key":"3325_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","volume":"127","author":"DB Evans","year":"1992","unstructured":"Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335\u20139.","journal-title":"Arch Surg"},{"key":"3325_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/PAS.0b013e31824104c5","volume":"36","author":"D Chatterjee","year":"2012","unstructured":"Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, et al. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012;36:409\u201317.","journal-title":"Am J Surg Pathol"},{"key":"3325_CR14","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1002\/cncr.26651","volume":"118","author":"D Chatterjee","year":"2012","unstructured":"Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118:3182\u201390.","journal-title":"Cancer"},{"key":"3325_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/bjs\/znaa031","volume":"108","author":"S van Roessel","year":"2021","unstructured":"van Roessel S, Janssen BV, Soer EC, Farina Sarasqueta A, Verbeke CS, Luchini C, et al. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review. Br J Surg. 2021;108:119\u201327.","journal-title":"Br J Surg"},{"key":"3325_CR16","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1028\u201361.","journal-title":"J Natl Compr Canc Netw"},{"key":"3325_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00428-017-2276-y","volume":"472","author":"L Bertero","year":"2018","unstructured":"Bertero L, Massa F, Metovic J, Zanetti R, Castellano I, Ricardi U, et al. Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why? Virchows Arch. 2018;472:519\u201331.","journal-title":"Virchows Arch"},{"key":"3325_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/jhbp.12056","volume":"31","author":"M Ishida","year":"2024","unstructured":"Ishida M, Fujii T, Kishiwada M, Shibuya K, Satoi S, Ueno M, et al. Japanese classification of pancreatic carcinoma by the Japan Pancreas Society: Eighth edition. J Hepatobiliary Pancreat Sci. 2024;31:755\u201368.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"3325_CR19","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.humpath.2012.01.020","volume":"43","author":"R Chetty","year":"2012","unstructured":"Chetty R, Gill P, Govender D, Bateman A, Chang HJ, Deshpande V, et al. International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems. Hum Pathol. 2012;43:1917\u201323.","journal-title":"Hum Pathol"},{"key":"3325_CR20","doi-asserted-by":"publisher","first-page":"18278","DOI":"10.1038\/s41598-020-74067-z","volume":"10","author":"Y Matsuda","year":"2020","unstructured":"Matsuda Y, Ohkubo S, Nakano-Narusawa Y, Fukumura Y, Hirabayashi K, Yamaguchi H, et al. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Sci Rep. 2020;10:18278.","journal-title":"Sci Rep"},{"key":"3325_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/MPA.0000000000001826","volume":"50","author":"S Mori","year":"2021","unstructured":"Mori S, Aoki T, Sakuraoka Y, Shimizu T, Yamaguchi T, Park KH, et al. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas. 2021;50:744\u201350.","journal-title":"Pancreas"},{"key":"3325_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","volume":"273","author":"MJ Truty","year":"2021","unstructured":"Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline\/Locally Advanced Pancreatic Cancer. Ann Surg. 2021;273:341\u20139.","journal-title":"Ann Surg"},{"key":"3325_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0000000000002672","volume":"268","author":"J He","year":"2018","unstructured":"He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetzis G, et al. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? Ann Surg. 2018;268:1\u20138.","journal-title":"Ann Surg"},{"key":"3325_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/PAS.0000000000001152","volume":"43","author":"SS Kim","year":"2019","unstructured":"Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, et al. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol. 2019;43:334\u201340.","journal-title":"Am J Surg Pathol"},{"key":"3325_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","volume":"34","author":"BV Janssen","year":"2021","unstructured":"Janssen BV, Tutucu F, van Roessel S, Adsay V, Basturk O, Campbell F, et al. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Mod Pathol. 2021;34:4\u201312.","journal-title":"Mod Pathol"},{"key":"3325_CR26","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1245\/s10434-023-14793-6","volume":"31","author":"S Vehvilainen","year":"2024","unstructured":"Vehvilainen S, Kuuliala A, Udd M, Nurmi A, Peltola K, Haglund C, et al. Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer. Ann Surg Oncol. 2024;31:2621\u201331.","journal-title":"Ann Surg Oncol"},{"key":"3325_CR27","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457\u201361.","journal-title":"Science"},{"key":"3325_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41698-024-00571-4","volume":"8","author":"M Abdelrahim","year":"2024","unstructured":"Abdelrahim M, Esmail A, Kasi A, Esnaola NF, Xiu J, Baca Y, et al. Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail. NPJ Precis Oncol. 2024;8:85.","journal-title":"NPJ Precis Oncol"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03325-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-026-03325-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03325-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:36:35Z","timestamp":1788928595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-026-03325-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3325"],"URL":"https:\/\/doi.org\/10.1007\/s00595-026-03325-w","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}